Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Paediatric Anaesthesia
|
February 24, 2006
Anesthetic management of staged separation of craniopagus conjoined twins
Michael Girshin, Carlene Broderick, Darshana Patel, et al.
Clinical Therapeutics
|
November 25, 2010
Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
John Davis, Frances Hackman, Marie-Noella Ndongo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 17, 2009
CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2
David M Asmuth, James Goodrich, David A Cooper, et al.
Cell Transplantation
|
March 25, 2016
The ixCELL-DCM Trial: Rationale and Design
Timothy D Henry, Gary L Schaer, Anthony DeMaria, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2
W David Hardy, Roy M Gulick, Howard Mayer, et al.
Plos One
|
October 16, 2010
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients
Nicholas Funderburg, Magdalena Kalinowska, James Eason, et al.
Pediatric Blood & Cancer
|
May 6, 2024
Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease
La'Kita M J Knight, Paula Tanabe, Audrey L Blewer, et al.
The Journal of Infectious Diseases
|
May 13, 2009
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1
Michael Saag, James Goodrich, Gerd Fätkenheuer, et al.
Clinical Therapeutics
|
February 15, 2011
Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis
Alan M Laties, Frederick T Fraunfelder, Konrad Tomaszewski, et al.
Clinical and Translational Science
|
August 2, 2024
A case study of inclusion of rural populations in research: Implications for science and health equity
Devon Noonan, Wendy K K Lam, James Goodrich, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Paediatric Anaesthesia
|
February 24, 2006
Anesthetic management of staged separation of craniopagus conjoined twins
Michael Girshin, Carlene Broderick, Darshana Patel, et al.
Clinical Therapeutics
|
November 25, 2010
Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
John Davis, Frances Hackman, Marie-Noella Ndongo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 17, 2009
CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2
David M Asmuth, James Goodrich, David A Cooper, et al.
Cell Transplantation
|
March 25, 2016
The ixCELL-DCM Trial: Rationale and Design
Timothy D Henry, Gary L Schaer, Anthony DeMaria, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2
W David Hardy, Roy M Gulick, Howard Mayer, et al.
Plos One
|
October 16, 2010
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients
Nicholas Funderburg, Magdalena Kalinowska, James Eason, et al.
Pediatric Blood & Cancer
|
May 6, 2024
Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease
La'Kita M J Knight, Paula Tanabe, Audrey L Blewer, et al.
The Journal of Infectious Diseases
|
May 13, 2009
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1
Michael Saag, James Goodrich, Gerd Fätkenheuer, et al.
Clinical Therapeutics
|
February 15, 2011
Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis
Alan M Laties, Frederick T Fraunfelder, Konrad Tomaszewski, et al.
Clinical and Translational Science
|
August 2, 2024
A case study of inclusion of rural populations in research: Implications for science and health equity
Devon Noonan, Wendy K K Lam, James Goodrich, et al.
Page
of 4